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Abstract: Background
Patients with chronic pancreatitis (CP) have an increased risk of pancreatic cancer. We
present the international consensus guidelines for surveillance of pancreatic cancer in
CP.
Methods
The international group evaluated 10 statements generated from evidence on 5
questions relating to pancreatic cancer in CP. The GRADE approach was used to
evaluate the level of evidence available per statement. The working group voted on
each statement for strength of agreement, using a nine-point Likert scale in order to
calculate Cronbach’s alpha reliability coefficient.
Results
In the following domains there was strong consensus: (1) the risk of pancreatic cancer
in affected individuals with hereditary pancreatitis due to inherited  PRSS1  mutations
is high enough to justify surveillance; (2) the risk of pancreatic cancer in patients with
CP associated with  SPINK1  p. N34S is not high enough to justify surveillance; (3)
surveillance should be undertaken in pancreatic specialist centers; (4) surveillance
should only be introduced after the age of 40 years and stopped when the patient
would no longer be suitable for surgical intervention. All patients with CP should be
advised to lead a healthy lifestyle aimed at avoiding risk factors for progression of CP
and pancreatic cancer. There was only moderate or weak agreement on the best
methods of screening and surveillance in other types of environmental, familial and
genetic forms of CP.
Conclusions
Patients with inherited  PRSS1  mutations should undergo surveillance for pancreatic
cancer, but the best methods for cancer detection need further investigation.
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ABSTRACT   
Background: Patients with chronic pancreatitis (CP) have an increased risk of pancreatic 
cancer. We present the international consensus guidelines for surveillance of pancreatic cancer 
in CP. 
Methods: The international group evaluated 10 statements generated from evidence on 5 
questions relating to pancreatic cancer in CP. The GRADE approach was used to evaluate the 
level of evidence available per statement. The working group voted on each statement for 
strength of agreement, using a nine-point Likert scale in order to calculate Cronbach’s alpha 
reliability coefficient. 
Results: In the following domains there was strong consensus: (1) the risk of pancreatic cancer 
in affected individuals with hereditary pancreatitis due to inherited PRSS1 mutations is high 
enough to justify surveillance; (2) the risk of pancreatic cancer in patients with CP associated 
with SPINK1 p. N34S is not high enough to justify surveillance; (3) surveillance should be 
undertaken in pancreatic specialist centers;  (4) surveillance should only be introduced after the 
age of 40 years and stopped when the patient would no longer be suitable for surgical 
intervention. All patients with CP should be advised to lead a healthy lifestyle aimed at 
avoiding risk factors for progression of CP and pancreatic cancer. There was only moderate or 
weak agreement on the best methods of screening and surveillance in other types of 
environmental, familial and genetic forms of CP. 
Conclusions: Patients with inherited PRSS1 mutations should undergo surveillance for 
pancreatic cancer, but the best methods for cancer detection need further investigation. 
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INTRODUCTION 
Chronic pancreatitis is a complex inflammatory disease with pain as the most dominant 
symptom.1 Pancreatic ductal adenocarcinoma (PDAC) can arise against a background of 
chronic pancreatitis although the relative risk varies considerably, in part because of other 
contributing factors including the duration of the disease, tobacco consumption, excess alcohol 
consumption, diet and physical activity, and late onset diabetes melitus.2 Mechanistically 
ongoing pancreatic parenchymal chronic inflammation is related to the acquisition of somatic 
KRAS mutations in pancreatic ductal cells and the development of pancreatic intraepithelial 
neoplasms, progressing to PDAC.3 Chronic pancreatitis can also promote acinar-to-ductal 
metaplasia, which has been linked to development of PDAC.4 The incidence of pancreatic 
cancer is approximately 10 per 105 per year with a slightly higher prevalence of around 12 per 
105 whilst the incidence and prevalence of chronic pancreatitis are estimated at 5-12 per 105 
per year and 50 per 105 respectively.5-11 The pooled relative risk estimates for pancreatic cancer 
among patients with CP varies from 2.7 to 13.3.12-15  Among all risk factors associated with 
pancreatic cancer, CP has the highest relative risk (RR) of greater than 2, with lower risk RR 
(<2) for tobacco smoking, diabetes mellitus (not treated with metformin), family history or 
metabolic syndrome.16 However, subsets of subjects with family history of pancreatic cancer 
or those with new-onset diabetes over age 50 years have much higher risks. Similarly, subsets 
of CP cohorts have markedly elevated risk of pancreatic cancer.17,18 Thus, guidelines on 
screening for pancreatic cancer in CP patients with the highest relative risk are important.   
Unlike sporadic chronic pancreatitis, the risk of PDAC in patients with autosomal dominant 
hereditary chronic pancreatitis, where the disease is due to gain-of-function mutations in the 
protease serine 1 (PRSS1) gene (e.g. p.N29I, p.R122H, p.A16V), appears to be much greater, 
with a relative risk of up to 87. 19-24  A study of patients with CP from Madras (tropical 
pancreatitis had an estimated relative risk of 100.25  Cystic fibrosis transmembrane conductance 
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regulator (CFTR) mutations in patients with chronic pancreatitis are also associated with a 
small increased relative risk of PDAC.26-30  There is no established direct association however, 
between other inherited genes, variants or polymorphisms in patients with chronic pancreatitis 
linked to pancreatic cancer including a the serine protease inhibitor Kazal type 1 (SPINK1), 
chymotrypsin C (CTRC), or carboxyl-ester lipase (CEL).30-38 A study by Muller et al however  
identified a hazard ratio  of 12.0 of PDAC in patients with pancreatitis carrying SPINK1 
variants  compared to patients with idiopathic pancreatitis but with a wide 95% confidence 
interval (CI) of 3.0-47.8.39  
The  key  determinants  for  screening  are  the  prevalence  of  the  disease, the accuracy of the 
screening methodology and the cost-benefit ratio of the screening.40,41 The prevalence of 
pancreatic cancer, is not high enough per se to justify general (primary) screening of the adult 
population. 40,41  The fundamental requirement for screening is for the true positive to false 
positive (TP:FP) ratio to be >1.0, since the proportion of false positives must not exceed that 
of true positives to a great extent. 40  If the TP:FP ratio is greatly below 1.0, then any benefit 
derived from screening is lost due to the excess morbidity and mortality. Assuming the 
prevalence of the at-risk population is 10 per 105 of the general adult population and the 
sensitivity and specificity of the conventional screening modalities for pancreatic cancer to be 
85%, then the TP:FP ratio is only 6 per 10–4, resulting in 1,764 false positives for each true 
positive.40  
Although several different treatment guidelines on chronic pancreatitis exist, the aim was to 
create a consensus guideline that is truly international and multidisciplinary, covering from 
development and early diagnosis to progression and treatment of chronic pancreatitis. To 
develop the first international guidelines on chronic pancreatitis, John Neoptolemos, David 
Whitcomb, Carlos Fernandez-Del Castillo, and Tooru Shimosegawa started at the European 
Pancreas Club (EPC) 2016 meeting on a joint venture with endorsement from the international 
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societies: International Association of Pancreatology (IAP), American Pancreatic Association 
(APA), Japan Pancreas Society (JPS) and the European Pancreatic Club (EPC). International 
experts were identified to have a multidisciplinary representation within subgroups focusing 
on 16 key topics of chronic pancreatitis. The first major step was the agreement on a new 
mechanistic definition of chronic pancreatitis.1 Thereon several other parts of the consensus 
guidelines were published, covering the early diagnosis of chronic pancreatitis, imaging of 
chronic pancreatitis and understanding and management of pain.42-44 This manuscript is another 
part of the international consensus guidelines, covering the topic on screening for pancreatic 
cancer in chronic pancreatitis. 
METHODS 
A team of 25 worldwide experts on pancreatic cancer surveillance in chronic pancreatitis with 
WG appointed as chair of the group. In 2016 the Presidents of the IAP, APA, JPS and EPC 
agreed to develop International Consensus Guidelines for Chronic Pancreatitis in collaboration 
with members of the respective organisations. The initial series of meetings occurred EPC 48th 
Annual Meeting, Liverpool UK, 6th -9th July 2016; 20th Scientific Meeting of the IAP in 
conjunction with the 47th Annual Meeting of the JPS and the 6th Meeting of the Asian- Oceanic 
Pancreatic Association. August 4th – 8th, 2016, Sendai International Center, Japan; APA, 47th 
Annual Meeting. Boston, MA, USA, 26th – 29th October 2016; PancreasFest 2017, Pittsburgh 
USA. July 28th 31st 2017; 21st IAP Meeting in conjunction with the Latin American Pancreatic 
Study Group (1st) Joint Meeting in Buenos Aires, Argentina, September 28-30, 2017. Based 
on a review of data from the relevant literature all experts presented their perspectives on the 
role of surgery and timing of intervention in the treatment of chronic pancreatitis. The method 
of the systematic literature review on articles on chronic pancreatitis was previously 
described.39-41 The international experts evaluated 10 statements generated from evidence on 5 
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questions deemed to be the most clinically relevant on pancreatic cancer surveillance in chronic 
pancreatitis. 
Grading 
The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) 
approach was used to evaluate the level of evidence per statement (see 
http://www.uptodate.com/home/gradingtutorial). Quality assessment of evidence was graded 
as ‘high’ if there was (very) low probability of further research substantially changing the 
conclusions, ‘moderate’ if further research might completely change the conclusions, and ‘low’ 
if further research was likely to completely change the conclusions. The strengths of the 
recommendation were graded as ‘strong’ if it was very certain that benefits outweigh risks and 
burdens, ‘weak’ if risks and burdens appear to be finely balanced, or when benefits, risks, and 
burdens are closely balanced or uncertain, or ‘conditional’ if it was in between strong and weak 
recommendation. 
Consensus 
After grading, the working group of international experts voted on the 10 statements for 
strength of agreement, using a nine-point Likert scale. Out of the results, a Cronbach's alpha 
reliability coefficient was calculated per statement (http://hdl.handle.net/1805/344). The voting 
results were classified for agreement as either; ‘strong’ if 80% of votes were 7 or above, 
‘conditional’ if 65% of votes were 7 or above, and ‘weak’ if less than 65% of votes were 7 or 
above. In addition, comments to each question and statements were compiled to explain the 
surrounding issues, supported by key references. An overview of results from the most 
important studies were tabulated and presented in the supplementary appendix. All statements 
and comments were reviewed by all authors to ensure the general relevance and applicability 
of the conclusions. Eventually a final draft of the document was generated and circulated to all 
authors for final editing and approval.  
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RESULTS 
Question 1: Should all patients with chronic pancreatitis undergo screening or surveillance for 
pancreatic cancer? 
Statement 1.1: The prevalence of pancreatic cancer in sporadic chronic pancreatitis is not high 
enough to justify screening or surveillance. 
Quality assessment: High; Recommendation: Conditional; Agreement: (= 74%). 
Statement 1.2: The risk of pancreatic cancer in affected individuals with an autosomal 
dominant history of hereditary pancreatitis due to inherited PRSS1 mutations is high enough to 
justify surveillance. 
Quality assessment: High; Recommendation: Strong; Agreement: (= 83%). 
Statement 1.3: The risk of pancreatic cancer in affected individuals with an autosomal 
dominant history of hereditary pancreatitis but without PRSS1 mutations is high enough to 
justify surveillance. 
Quality assessment: Moderate; Recommendation: Weak; Agreement: (= 57%). 
Statement 1.4: The risk of pancreatic cancer in patients with chronic pancreatitis associated 
with SPINK1 p. N34S is not high enough to justify screening or surveillance. 
Quality assessment: Moderate; Recommendation: Strong; Agreement: (= 80%). 
Statement 1.5: The risk of pancreatic cancer in patients with chronic pancreatitis associated 
with other germline mutations including those of CFTR, CTRC, CPA1, and CEL, is not high 
enough to justify screening or surveillance. 
Quality assessment: Moderate; Recommendation: Conditional; Agreement: (= 70%). 
Comment 
The pooled relative risk estimates for pancreatic cancer among patients with sporadic chronic 
pancreatitis in two collective studies ranged from 2.7 to 13.312, 13   Duell et al analysed 10 case-
control studies involving 5,048 cases of pancreatic cancer and 10,947 controls taking part in 
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the International Pancreatic Cancer Case-Control Consortium (PanC4). The association 
between chronic pancreatitis and pancreatic cancer (at intervals of >2 years between diagnoses) 
had an odds ratio of 2.71 (95% Confidence Interval [CI] = 1.96-3.74).13  Bang et al using 
nationwide data from Danish registries from 1995 through 2010, evaluated 11,972 patients 
with CP and 71,814 person-years compared with 119,720 age- and sex-matched controls and 
917,436 person-years observation.45 A history of pancreatitis was associated with a hazard ratio 
for pancreatic cancer of 6.9 (95% CI: 5.6–8.6) .45  Different estimations of pancreatic cancer 
risk based on multiple meta-analyses in patients with CP are summarized in Table 1.12-15 Given 
the short life expectancy of pancreatic cancer patients the incidence tends to equal that of 
prevalence and thus this level of prevalence is insufficient for screening in patients with CP.40  
The relative risk for pancreatic cancer in patients with autosomal dominant hereditary chronic 
pancreatitis due to PRSS1 mutations is of up to 87 although the estimates are very wide.19-24 
The risk of pancreatic cancer might be reduced by measures introduced to minimize the 
progression of chronic pancreatitis such as cessation of smoking and alcohol consumption as 
well as prophylactic total pancreatectomy in selected cases.2,46-49  
Following a call to members of the APA and the IAP to participate in a longitudinal study of 
hereditary pancreatitis, 37 physicians from 10 countries contributed records of 246 patients 
with early age (<30 years) symptom onset and a positive family history from April 1995 to 
February 1996.19 Reporting in March 1997, there were eight new pancreatic cancers during 
8,531 person-years of follow-up, with a standardized incidence ratio of 53 (95% CI = 23-105).19 
The estimated cumulative risk of pancreatic cancer to age 70 years was 40% (95% CI = 9-
71%).19  
A registry study based on families with sequenced PRSS1 mutations by the European Registry 
of Hereditary Pancreatitis and Pancreatic Cancer EUROPAC) identified 418 affected 
individuals from 112 families in 14 countries, 58 (52%) families with the PRSS1 p.R122H, 24 
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(21%) the PRSS1 p.N29I, and 5 (4%) with the PRSS1 p.A16V mutation, plus 2 with rare 
mutations, and 21 (19%) with no PRSS1 mutation.22 Participants in the registry were contacted 
prospectively on a regular basis. Three hundred seventy-five patients (from 111 families) with 
follow-up data were observed over an observation period of 14,064 person years with 20 (5%) 
pancreatic cancers being detected (1 cancer per 703 person years of follow-up).22 The 
cumulative risk for pancreatic cancer was 44.0% (95% CI = 8.0-80.0%) at 70 years from 
symptom onset with a standardized incidence ratio of 67 (95% CI =50-82).22   
An update of the EUROPAC study in 2010 reported a total of 37 pancreatic cancer cases 
amongst 652 affected individuals from 149 Hereditary Pancreatitis families; there were 19 
PDAC cases amongst 336 affected individuals from 71 PRSS1 p.R122H families; there were 
10 PDAC cases amongst 157 affected individuals from 32 PRSS1 p.N29I families; there were 
three PDAC cases amongst 19 affected individuals from 10 A16V families; and there was one 
PDAC case amongst  10 affected individuals from  families with other PRSS1 mutations.50  
Similar to the original report there were 10 PDAC cases amongst 134 affected individuals from 
37 families with an autosomal dominant family history but without any PRSS1 mutations or 
deleterious variants/mutations of the SPINK1, CFTR and CTRC genes.50 
A study of patients living in France, was based on contacting all clinical gastroenterologists 
and pediatricians and genetics laboratories in the country from 2005 with response rates of 84% 
and 100% respectively.23 Included in the analyses were 200 patients from 78 families with 
6,673 person-years follow-up of whom 135 (67.5%) had a PRSS1 mutation (p.R122H in 78%, 
p.N29I in 12%, and other mutations in 10%).23  A pancreatic adenocarcinoma was diagnosed 
in ten patients (two were still alive at the census point) resulting in a cumulative risk at age 75 
years were of 53.5% (95% CI = 7-76%).23 
A recent study of USA patients organized from Pittsburgh, recruited 217 PRSS1 carriers 
including 83.9% with PRSS1 p.R122H and 11.5% with PRSS1 p.N29I mutations from 1995–
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2013.24  Individual follow-up was not possible in all patients and so the Social Security Death 
Index (SSDI), and the National Death Index (NDI) through the National Center for Health 
Statistics (NCHS) were used to determine outcomes. Through this method they identified 
deaths in 37 PRSS1 mutation carriers, five from pancreatic cancer with a standardized 
incidence ratio of 59 (95% CI = 19-138), and a cumulative risk at 70 years of 7.2% (95% CI = 
0-15.4%).24 The observation period in person years was not mentioned and actual number of 
cases of pancreatic cancer could not be determined. 24 
There are no tests currently available that could be regarded as screening tests and therefore 
diagnostic measures would be required for early detection. Carbohydrate antigen (CA)19-9, 
which has some utility in identifying pancreatic cancer in patients without pancreatitis, cannot 
be recommended in patients with CP as they often have raised CA19-9 in the absence of cancer, 
secondary to parenchymal inflammation.51 The recent guidelines from the UK National 
Institute for Health and Care Excellence recommend that surveillance for pancreatic cancer is 
offered to people with hereditary pancreatitis and a PRSS1 mutation.52  
The relative risk of pancreatic cancer in patients with cystic fibrosis and/or CFTR mutation 
carriers with/or without chronic pancreatitis is significantly increased but less so than that in 
patients with hereditary pancreatitis from PRSS1 mutations.26-30  A study of 28,511 patients 
with cystic fibrosis from 1985 through 1992 in the United States and Canada identified 13 
digestive tract cancers, during 164,764 person-years of follow-up, giving a ratio of observed to 
expected cancers of 6.5 (3.5 to 11.1) but there was only one case of pancreatic cancer.26  As 
part of the same study the estimated numbers of patients with cystic fibrosis in 1992 as reported 
to the International Cystic Fibrosis Association, from 17 countries was approximately 24,500 
with two cases of pancreatic cancer, giving an odds ratio of 31.5 with very wide confidence 
intervals (95 % CI = 4.8-205). 26  An analysis of nine patients with cystic fibrosis and pancreatic 
cancer identified from 1985 to 2006 reported from the USA, UK Germany, and Switzerland by 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
IAP – APA – JPS – EPC ICGCP: Surveillance for cancer in CP                                        4 May 2020 
Page 13 of 35 
 
Maisonneuve et al was equivalent to an incidence of approximately 1 per 105 per year with a 
risk ratio of 5.3 (95% CI = 2.4-10.1).28  They concluded that although the estimated risk of 
pancreatic cancer in cystic fibrosis was “greater than in the general population, compared with 
other causes of mortality, the absolute risk of pancreatic cancer in patients with cystic fibrosis 
is negligible”. 28  A further study by Maisonneuve et al followed 41,188 patients who received 
care at 250 cystic fibrosis care center programs in the USA from 1990 to 2009, with 344,114 
patient-years of observation of non-transplanted patients and found only one pancreatic cancer, 
giving standardized incidence ratio of 0.8 (95% CI = 0.0- 4.2).53  A recent meta-analysis six 
cohort studies with 99,925 patients with cystic fibrosis providing 544,695 person-years by 
Yamada et al, found a pooled standardized incidence ratio for pancreatic cancer of 6-18 (95% 
CI= 1.31-29.27).54  Maisonneuve et al commented that “the low absolute number of patients 
with cancer, the lack of a well-established screening test, and the high burden of additional 
testing do not support the strong screening recommendations for pancreatobiliary cancers made 
by Yamada and colleagues”.55  
McWilliams et al tested 949 patients with pancreatic cancer to see if they were also carriers of 
one or more of the 39 common cystic fibrosis-associated CFTR mutations and compared these 
to 13,340 case controls from a clinical laboratory database for prenatal testing for CFTR 
mutations.29  Fifty (5.3%) of the patients with pancreatic cancer carried a common CFTR 
mutation compared to 510 (3.8%) of the controls, giving an odds ratio of 1.40 (95% CI = 1.04-
1.89) and those with cancer more likely to be younger when diagnosed (<60 years), and more 
likely to be smokers.29  
Nearly all studies have not shown any direct association however, between most other inherited 
genes, variants or polymorphisms in patients with CP linked to pancreatic cancer, including 
SPINK1, CTRC, and CEL.30-38,53-56   A recent study combining 209 patients with pancreatitis 
and the SPINK1 p.N34S variant from two France centers and one England center identified 
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seven cancers compared to three cancers in 302 patients with idiopathic pancreatitis (hazard 
ratio of 12.0, 95% CI = 3.0-47.8).39  
Whilst variants in carboxypeptidase A1 (CPA1) have been identified in patients with chronic 
pancreatitis from Europe and India (although not in Han Chinese), and separately in patients 
with PDAC from high risk families, there is no direct evidence to link  CPA1 variants in chronic 
pancreatitis patients with a risk of PDAC.55-59  Functionally impaired CPA1 variants were found 
in 29/944 (3.1%) cases from Germany and in 5/3,938 (0.1%) matched controls, in 8/600 (1.3%) 
cases in a repeat set from Europe, and in 9/2,432 (0.4%) of their controls,  from India in 5/230 
(2.2%) cases and 0/264 controls, and from Japan in 5/247 (2.0%) cases and in 0/341 controls.57 
A study in Han Chinese found only three (0.27%) functionally impaired CPA1 variants from 
1,112 patients with idiopathic chronic pancreatitis versus two (0.13%)  out of 1,580 in controls, 
but without a significant association.58  Tamura and colleagues from John Hopkins University, 
identified CPA1 variants in seven patients with PDAC from a combined set of hospital and 
familial pancreatic cancer cases compared with one in 2,012 controls giving an odds ratio of 
9.36 (95% CI = 1.15-76.02).59  The authors concluded that patients with CPA1 variants could 
potentially benefit from pancreatic cancer screening and surveillance, but added that  further 
investigation was needed to determine their lifetime risk of pancreatic cancer.59  The recent 
evidence report for the US Preventive Services Task Force on screening identified 18 cases of 
PDAC in 1,317 high familial risk individuals from 13 studies, only 12 of which were at an 
early stage and noted that that there was no direct evidence of the effect of screening on 
morbidity or mortality.60  
The relative risk of pancreatic cancer in patients with chronic pancreatitis in patients from India 
appears to be different from that in Europe and North America with differences in genetic and 
environmental risk factors.61  In India SPINK1 variants are associated with idiopathic chronic 
pancreatitis in 31.8-44% of cases, CFTR mutations in 9-32.6% of cases, CTRC mutations in 
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5.4-12.5% of cases and an odds ratio of 1.57-1.62 for the MORC4/CLDN2 locus.62  A study by 
Chari et al in 1994 followed 185 patients with chronic pancreatitis from the Diabetes Research 
Center in Madras, India for an average of 4.5 years.25  There were six deaths from cancer of 
the pancreas (average age at onset of 45.6 +/- 7.3 years) with a relative risk of 100.2 (95% CI 
= 37-218).25  A more recent study from the All India Institute of Medical Sciences, New Delhi, 
India of  402 patients with chronic pancreatitis with 3967 person-years of exposure, five 
patients developed pancreatic cancer (four with idiopathic, and one with hereditary chronic 
pancreatitis) after 16.60 ± 3.51 years of chronic pancreatitis (since diagnosis), giving a  
standardized incidence ratio of 121 (95% CI = 39.7–295.9) .61 In a separate case-control study, 
24 of 249 patients with pancreatic cancer had idiopathic chronic pancreatitis (none had alcohol-
related pancreatitis) at a mean age of 45.6 ± 12.2 years, which gave an odd ratio of 97.7 (95% 
CI, = 12.7–751.4) compared to 1000 healthy controls after multivariable analysis .62 In this 
study the proportion of patients with pancreatic cancer and underlying chronic pancreatitis who 
had a SPINK1 variant (61.5%; 16 of 26 patients) was not significantly different from  the 
proportion of patients with idiopathic chronic pancreatitis in the cohort study who had a 
SPINK1 variant (47.8%; 32 of 67 patients).62 
 
Question 2: What are the best available surveillance methods? 
Statement 2.1: The best available surveillance methods are CT and MRI. 
Quality assessment: Weak; Recommendation: Conditional; Agreement: (= 70%). 
Statement 2.2: EUS should not be used for surveillance as early tumors may be obscured by 
inflammation, fibrosis and calcification. 
Quality assessment: Moderate; Recommendation: Weak; Agreement: (= 52%). 
Comment 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
IAP – APA – JPS – EPC ICGCP: Surveillance for cancer in CP                                        4 May 2020 
Page 16 of 35 
 
There are no standard methods available for screening for early pancreatic cancer, even in high 
risk individuals. Therefore, surveillance would need to be undertaken using standard diagnostic 
techniques. Pancreas specific dual contrast multi-slice computed tomography (CT) is 
particularly useful in the diagnosis of pancreatic tumors.44,63,64  Magnetic resonance imaging 
(MRI) and magnetic resonance cholangio-pancreatography (MRCP), with or without secretin 
stimulation of pancreatic duct flow can also be used to identify pancreatic cancer.65-69  
Endoluminal ultrasonography (EUS) is useful in helping to identify early pancreatic cancer 
against a normal pancreatic parenchyma. Identifying pancreatic cancer in the background of 
chronic pancreatitis is more difficult and early cancer may not be distinguishable against a 
background of parenchymal fibrosis and calcification in chronic pancreatitis.70-72   CT can be 
performed in general hospitals with no access to EUS or MRI and is less time consuming and 
a cheaper alternative than most secondary investigations.44  Whilst evidence for the use of EUS 
in surveillance for early pancreatic cancer that is curable in chronic pancreatitis is lacking, it is 
established as a diagnostic tool in cases of a suspicious lesion, although surgical resection 
remains the final option.52,73-78 
 
Question 3: Where should surveillance for pancreatic cancer in patients with hereditary 
pancreatitis due to PRSS1 mutations be undertaken?  
Statement 3.1: Surveillance for pancreatic cancer in patients with hereditary pancreatitis due 
to PRSS1 mutations should be undertaken in pancreatic specialist centers.  
Quality assessment: Low; Recommendation: Strong; Agreement: (= 100%). 
Comment 
At the Fourth International Symposium of Inherited Diseases of the Pancreas in Chicago 2003 
a key recommendation was that testing for PDAC in high risk groups should be performed only 
within the context of peer-reviewed protocols.79  Pancreatic specialist canters are best 
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positioned to have experience in the progressive development of the optimum and most 
pragmatic approaches to screening and surveillance.80  Leading centers can centralize registries 
and promote surveillance for participating centers at a national level such as the National 
Familial Pancreas Tumor Registry (NFPTR) established at Johns Hopkins in 1994 by Ralph 
Hruban, and EUROPAC established at Liverpool in 1996 by John Neoptolemos.81 There is 
increasing interest  in using endoscopic duodenal lumen juice aspiration to detect premalignant 
changes in the main pancreatic duct.82-83   
 
Question 4: When should surveillance be initiated and stopped in hereditary pancreatitis? 
Statement 4.1: Surveillance should only be introduced after the age of 40 years and stopped 
when the patient would no longer be suitable for surgical intervention. 
Quality assessment: Moderate; Recommendation: Strong; Agreement: (= 97%). 
Comment 
The largest series of patients with hereditary pancreatitis and pancreatic cancer is from 
EUROPAC, 26 (6%) patients diagnosed with pancreatic cancer out of 418 affected patients, 
with the risk increasing from the age of 40 years onwards.22  A similar increase in risk from 40 
years was reported by the APA and the IAP study with eight patients with pancreatic cancer 
from a cohort of 246 patients.19 The study by Shelton et al with 217 PRSS1 carriers (181 
symptomatic) identified pancreatic cancer in five individuals, three symptomatic carriers and 
in two asymptomatic carriers, at a median age of death of 69 years with a range of 51-76 years.22   
A study from the German Registry of Hereditary Pancreatitis in Leipzig and Munster 
University in Germany reported on 101 subjects with PRSS1 mutations (75 symptomatic). Only 
three of these patients were diagnosed with pancreatic cancer,  with a median of 23 years (range 
10-33) years after the onset of pancreatitis.21  This was a ‘snap-shot’ study without prospective 
follow-up and included 25 patients who had had pancreatic surgery, out of 75 symptomatic 
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patients.21  In a recent study from India of 402 patients with chronic pancreatitis from any 
cause, there were five cases with pancreatic cancer diagnosed at a mean age of diagnosis of 
50.9 years with a standard deviation of 10.1 years.62  
To address the threshold for screening given as 40 years of age, the risk of missing a case of 
pancreatic cancer and the cost benefit of screening higher risk individuals must be balanced. 
Lowenfels et al followed 497 Hereditary Pancreatitis patients observing 19 pancreatic cancer 
cases, only three of whom developed pancreatic cancer before the age 40 and all three were 
smokers.85  Suggesting little benefit of beginning screening before the age of 40, at least in 
non-smokers.  
The frequency of surveillance will depend on the protocol being followed and may be modified 
according to molecular testing. There is no specified age to cease surveillance, as the risk 
continues to rise with age.19-22   A simple guide is to consider stopping surveillance when the 
patient has such a fall in performance status that they would not be able to have either curative 
surgical treatment and/or palliative chemotherapy if the diagnosis of PDAC was made. 
 
Question 5: What advice should patients with chronic pancreatitis be given in managing their 
disease in order to reduce risk of developing PDAC? 
Statement 5.1: Patients should be advised to avoid use of tobacco, not drink alcohol, have a 
balanced healthy diet containing daily fruit and vegetables with a high folate intake, whilst 
moderating the intake of red meat and taking some form of regular high physical exercise, 
altogether aiming to avoid obesity. 
Quality assessment: Moderate; Recommendation: Strong; Agreement: (= 91%). 
Comment 
Measures that might help to reduce the progression of chronic pancreatitis, may also directly 
and indirectly help to reduce the risk from developing pancreatic cancer, namely avoiding 
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tobacco and alcohol consumption.2  There are also additional risk factors for PDAC that may 
be divided into genetic risk factors and environmental risk factors.16,17,86   Individuals at high 
risk for PDAC include individuals with hereditary pancreatitis, as well as those with  strong 
family history of pancreatic cancer, or familial cancer syndromes that include pancreatic 
cancer.16-19,22,40,41,80,86 Those at particularly high risk include those individuals with hereditary 
pancreatitis due to PRSS1 mutations and cancer causing germline mutations.17,19,22,40,41,50,80 
Risk factors and factors that are protective of PDAC are shown in Table 2.86    
Brown et al estimated that lifestyle and environmental factors accounted for 31.5% of all 
pancreatic cancers in the UK in 2015.87 The contribution of tobacco smoking is 20-30% of all 
PDAC cases, alcohol consumption >30 (3.75 units) g /day accounts for <10%, whilst the 
attributable fraction for obesity varies from 3% to 27%.16,86,87   The top six of the twelve 
recommendations of the European Code against Cancer are directly relevant to helping to 
prevent pancreatic cancer (Table 3).88  The USA NIH-AARP (American Association of Retired 
Persons) Diet and Health Study, identified 1,057 cases of PDAC from 450,416 participants 
aged 50–71 years who had completed a diet and lifestyle questionnaire (1995–1996) followed 
up to December 2003.89  It was estimated that around 30% of PDAC cases were attributable to 
low healthy lifestyle scores that could have been prevented.89 
 
DISCUSSION 
The risk of pancreatic cancer might be reduced by measures introduced to minimize the 
progression of chronic pancreatitis such as cessation of smoking and alcohol consumption as 
well as prophylactic total pancreatectomy.2,45-49,85  Thus, variations in the estimates of relative 
risk are in part explained by differences in ascertainment of incident cases and the study design 
including the method of follow up, as well the impact of intervention (life-style, and medical 
and surgical measures) in prospectively followed up cohorts. In addition, although the number 
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deaths from pancreatic cancer might be ascertained, the total number of cases might not 
necessarily be established. 
There was a strong consensus that affected individuals with an autosomal dominant history of 
hereditary pancreatitis due to inherited, gain-of-function PRSS1 mutations should undergo 
surveillance but not patients with CP associated with SPINK1 p.N34S. The number of cancers 
associated with SPINK1 p. N34S is quite small and with a very wide confidence interval 
warranting further prospective studies.39 Surveillance in affected individuals with an autosomal 
dominant history of hereditary pancreatitis but without PRSS1 mutations was only weakly 
supported. The cumulative risk in this group of patients was not dissimilar to the group with 
gain-of-function PRSS1 mutations comprising 21 (19%) of the 418 affected individuals in the 
EUROPAC Registry, indicating the need for further studies.22 There was only  conditional 
agreement for surveillance in patients with CP associated with other germline mutations of 
CFTR, CTRC, CPA1, and CEL due to the low relative risk of pancreatic cancer. 30-38,53-60 The 
was conditional agreement that the best available surveillance methods were CT and MRI, and 
only weak agreement on the use of EUS as early tumors might be obscured by inflammation, 
fibrosis and calcification, and also there was a lack of any reported cases of early tumor 
detection in hereditary pancreatitis by EUS. There was strong agreement that surveillance for 
pancreatic cancer should be undertaken in pancreatic specialist centers, to be introduced after 
the age of 40 years and stopped when the patient would no longer be suitable for surgical 
intervention. There was strong agreement that patients should be advised to avoid use of 
tobacco, not drink alcohol, and advised about a balanced healthy diet.86 
Altogether, we require better estimates of pancreatic cancer relative risk in CP, in different 
countries around the world, and we need more outcome information on prospective 
surveillance in hereditary pancreatitis.  In addition, we need better overall disease models 
where the interaction of multiple risk factors and their cumulative or potentiating effects can 
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be defined and were guidance on the use of early detection biomarkers can be accurately 
defined.90,91 
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Table 1: Summary of pancreatic cancer relative risk in patients with chronic 
pancreatitis. 
 
Author, year 
 
Type of 
review 
Number of 
studies 
Strata Summary 
Relative Risk 
(95% CI) 
Raimondi et al, 
201012 
Meta-analysis 
(16124 cases) 
12 case-control-studies 
10 cohort studies 
 
Pancreatitis, unspecified  
Chronic pancreatitis  
Chronic pancreatitis (> 2 years) 
Hereditary pancreatitis  
Tropical pancreatitis 
5.1 (3.5-7.3) 
13.3 (6.1-28.9) 
5.8 (2.1-15.9) 
69.0 (56.4-84.4) 
100. (37.0-218.) 
Duell et al, 
201213 
Pooled analysis 
(5048 cases) 
10 case-control studies Pancreatitis not otherwise specified 
(> 2 years) 
2.71 (1.96-3.74) 
Kirkegård, et 
al 201714 
 
Meta-analysis 
(4098 cases) 
4 case-control studies 
9 cohort studies 
No lag period 
1-year lag period 
2-year lag period 
5-year lag period 
Minimum 9-year lag period 
7.96 (2.36-26.9) 
6.09 (3.79-9.79) 
16.16 (12.6-20.7) 
7.90 (4.26- 14.7) 
3.53 (1.69-7.38) 
Tong et al, 
201415 
 
Meta-analysis 
(14667 cases) 
14 case-control studies 
3 cohort studies 
Pancreatitis 
Chronic pancreatitis 
Acute pancreatitis 
Diagnosis within 1 year 
Diagnosis for no less than 2 years 
Diagnosis for no less than 5 years 
Diagnosis for no less than 10 years 
7.05 (6.42-7.75) 
10.3 (9.13-11.7) 
2.12 (1.59-2.83) 
23.3 (14.0-38.9) 
3.03 (2.41-3.81)  
2.82 (2.12-3.76)  
2.25 (1.59-3.19) 
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Table 2. Risk and protective factors for pancreatic cancer. *Factors that are amenable to 
primary prevention are highlighted. Modified from Maisonneuve and Lowenfels.86 
High Risk 
Relative risk >2.0 
Moderate Risk 
Relative risk =1.5-2.0 
Low Risk 
Relative risk =1.1-1.5 
Protective 
Relative risk <1.0 
Hereditary pancreatitis 
Relative risk = 10-70 
Family history 
Relative risk = 1.8 
Metabolic syndrome 
Relative risk = 1.5 
*Fruits and vegetables 
Relative risk = 0.7 
Germline mutations 
Relative risk = 5-30 
Long-term diabetes 
mellitus 
Relative risk = 1.8 
Helicobacter pylori 
Relative risk = 1.5 
*High dietary folate 
Relative risk = 0.7 
Chronic pancreatitis 
Relative risk = 5-10 
*Tobacco smoking 
Relative risk = 1.7 
*Obesity 
Relative risk = 1.3 
Atopic Allery 
Relative risk = 0.7 
  Non-O blood group 
Relative risk = 1,3 
*High physical activity 
Relative risk = 0.9 
  *Alcohol > 30g (3.8 
units) per day 
Relative risk = 1.2 
 
  *Red meat consumption  
Relative risk = 1.2 
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Table 3. The top six of the twelve recommendations of the European Code against Cancer 
to prevent cancer: directly relevant to pancreatic cancer prevention.88 
Recommendations 
1. Do not smoke. Do not use any form of tobacco. 
2. Make your home smoke free. Support smoke-free policies in your workplace. 
3. Take action to be a healthy body weight. 
4. Be physically active in everyday life. Limit the time you spend sitting. 
5. Have a healthy diet: 
 Eat plenty of whole grains, pulses, vegetables and fruits. 
 Limit high-calorie foods (foods high in sugar or fat) and avoid sugary 
drinks. 
 Avoid processed meat; limit red meat and foods high in salt. 
6. If you drink alcohol of any type, limit your intake. 
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